Valeant (VRX) to Buy Provenge From Dendreon

Valeant Pharmaceuticals (VRX) announces that it has entered into a so-called stalking horse agreement with bankrupt drugmaker Dendreon Corp. for the worldwide rights to its prostate cancer vaccine, Provenge, and certain other assets for $296 million. The deal, which allows Quebec-based Valeant to be the preferred bidder and also entitled to a break-up fee and […] View the full post at: Valeant (VRX) to Buy Provenge From Dendreon Related posts: And Now Deflation eBay Looking to Sell StumbleUpon Alibaba Ready To Buy Back Yahoo Stake